Alpha 2.0
Login Register
» Articles » PMID: 31622366

Switching to Bedaquiline for Treatment of Rifampicin-resistant Tuberculosis in South Africa: A retrospective Cohort Analysis

Overview
Journal PLoS One
Specialties General Medicine
Science
Date 2019 Oct 18
PMID 31622366
Citations 2
Authors
Tara C Bouton
Margaretha De Vos
Elizabeth J Ragan
Laura F White
Leonie Van Zyl
Danie Theron
C Robert Horsburgh
Robin M Warren
Karen R Jacobson
Affiliations
Soon will be listed here.
Abstract

South Africa led the world with guidelines on bedaquiline (BDQ) use as a single drug substitution to manage rifampin resistant tuberculosis regimen toxicity. We examined reasons for giving BDQ in a retrospective cohort: >75% of patients were switched to BDQ for toxicity (ototoxicity or renal dysfunction) rather than drug resistance.

Citing Articles

Spatial heterogeneity of extensively drug resistant-tuberculosis in Western Cape Province, South Africa.

Sy K, Leavitt S, De Vos M, Dolby T, Bor J, Horsburgh Jr C Sci Rep. 2022; 12(1):10844.

PMID: 35760977 PMC: 9237070. DOI: 10.1038/s41598-022-14581-4.

Effectiveness of the Novel Anti-TB Bedaquiline against Drug-Resistant TB in Africa: A Systematic Review of the Literature.

Traore A, Rikhotso M, Banda N, Mashilo M, Ngandu J, Mavumengwana V Pathogens. 2022; 11(6).

PMID: 35745490 PMC: 9229213. DOI: 10.3390/pathogens11060636.

References
1.
Schnippel K, Firnhaber C, Berhanu R, Page-Shipp L, Sinanovic E . Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis. J Antimicrob Chemother. 2017; 72(7):1871-1879. DOI: 10.1093/jac/dkx107. View
2.
Guglielmetti L, Hewison C, Avaliani Z, Hughes J, Kiria N, Lomtadze N . Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries. Int J Tuberc Lung Dis. 2017; 21(2):167-174. PMC: 5664221. DOI: 10.5588/ijtld.16.0493. View
3.
Dheda K, Cox H, Esmail A, Wasserman S, Chang K, Lange C . Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?. Respirology. 2017; 23(1):36-45. DOI: 10.1111/resp.13143. View
4.
Murray C, Ortblad K, Guinovart C, Lim S, Wolock T, Roberts D . Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384(9947):1005-70. PMC: 4202387. DOI: 10.1016/S0140-6736(14)60844-8. View
5.
Villellas C, Coeck N, Meehan C, Lounis N, de Jong B, Rigouts L . Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother. 2016; 72(3):684-690. PMC: 5400087. DOI: 10.1093/jac/dkw502. View